Castleman’s disease is an uncommon lymphoproliferative disorder that may
be localized to a single lymph node (unicentric) or occur systemically
(multicentric). It is a non-cancerous growth of the lymph nodes and related
tissues, but it is associated with a higher risk of a type of cancer called
lymphoma.
Affected patients have an increased risk of infection, kidney failure
and certain cancers. Castleman’s disease is life threatening, especially for
patients with more than one affected lymph node. The most common Symptoms are high fevers, anemia, weight
loss, loss of appetite, and low white blood cell counts, which may to be due to
the overproduction of interleukin 6.
Sylvant (siltuximab), a medicine for the treatment of adult patients
with multicentric Castleman’s disease who are HIV negative and human
herpesvirus‑8 (HHV‑8) negative have received European Medicines Agency (EMA) recommendation
for MAA under orphan legislation. The active substance of Sylvant is
siltuximab, a human‑mouse chimeric monoclonal antibody that specifically binds
to and neutralizes human IL-6 with high affinity.
There are currently no medicinal products authorized in the European
Union (EU) for the treatment of Castleman’s disease. In clinical trials,
Sylvant has shown its ability to reduce tumour burden and improve the symptoms
of the disease with a safety profile.
The CHMP opinion on Sylvant will now be sent to the European Commission
for adoption of a decision on an EU-wide marketing-authorization.
For more details refer http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/03/news_detail_002048.jsp&mid=WC0b01ac058004d5c1
No comments:
Post a Comment